Northwire Canada EditionThursday, July 16, 2026
Sign inSubscribe
Northwire
⌕
CLCH 1.17 −4.1% DG 0.035 +0.0% SGML 15.86 −6.0% FURY 0.730 −2.7% CG 22.11 −1.9% ARIS 20.18 −1.1% LAF 1.65 +0.0% MKO 10.18 −2.2% NUG 0.330 −1.5% SGN 0.250 −5.7% AVL 7.99 −0.4% ELE 22.14 −2.7% TRX 1.03 −7.2% PTM 1.83 +0.6% OMM 0.050 −9.1% CBG 0.300 −1.6% CLCH 1.17 −4.1% DG 0.035 +0.0% SGML 15.86 −6.0% FURY 0.730 −2.7% CG 22.11 −1.9% ARIS 20.18 −1.1% LAF 1.65 +0.0% MKO 10.18 −2.2% NUG 0.330 −1.5% SGN 0.250 −5.7% AVL 7.99 −0.4% ELE 22.14 −2.7% TRX 1.03 −7.2% PTM 1.83 +0.6% OMM 0.050 −9.1% CBG 0.300 −1.6%
Other

Nxera Pharma to Receive US$3.6 Million in Milestone Payment Pursuant to Research Collaboration with Centessa

By The Northwire Desk — AI Analysis Jan 13, 2026 · 03:09 4565 · None None
4565 · Price

Executive Summary

  • Centessa Pharmaceuticals achieved an early development milestone for its OX2R agonist ORX142, triggering a $3.6 million payment to Nxera Pharma under their research collaboration.
  • The milestone payment will be recognized as revenue in Nxera’s Q4 FY2025 results.
  • The achievement reflects progress on a candidate targeting neurological and neurodegenerative disorders.

Key Details

  • Milestone: Early development milestone for ORX142 (orally administered, highly potent and selective orexin‑2 receptor agonist).
  • Payment Amount: US $3.6 million payable to Nxera Pharma.
  • Recognition: The payment will be recorded as revenue in Q4 FY2025.
  • Collaboration Context: Payment is pursuant to the existing research collaboration agreement between Nxera Pharma and Centessa Pharmaceuticals.
  • Therapeutic Focus: ORX142 is being developed for treatment of neurological and neurodegenerative disorders.

Notable Quotes

(No direct quotes were provided in the release.)

Read the original news release →

More from None

Jun 30, 2026 · 04:27

AI-driven GPCR drug discovery platform monetizing partnerships while transitioning to a profitable specialty pharma model in APAC.

Other Jun 10, 2026 · 02:35

AI-driven GPCR drug discovery platform accelerates pipeline through strategic consortium membership and milestone-driven revenue turnaround.

M&A / Property Jun 01, 2026 · 19:30

Nxera Accelerates Vamorolone Rollout in South Korea as APAC Specialty Pharma Strategy Gains Traction

Regulatory May 11, 2026 · 02:34

GPCR spin-out reels in $275M in biobucks and equity, keeping Asia rights and cash burn in check

M&A / Property May 08, 2026 · 06:26

Nxera Pharma Defends Core IP Amidst Profitability Turnaround

Regulatory May 01, 2026 · 02:36

Nxera Pharma Turns Profitable on Milestone Surge, But Cash Burn Raises Liquidity Questions

Earnings